SVS | Jotup

Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis

Retrieved on:

星期四, 五月 9, 2024

Cancer, OGM, Chord diagram (information visualization), Doctor of Philosophy, Aneuploidy, VIA, Classification, Genomics, SVS, SAN, Medical imaging

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis.

Key Points:

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis.
These advancements to the company’s VIA™ software solution enhance the detection and interpretation of aneusomies, and improve the analysis, visualization, interpretation, and reporting of data types including optical genome mapping (OGM), next generation sequencing, and microarray, for comprehensive assessment of hematological diseases.
These advancements to our VIA software and Bionano Solve pipeline offer researchers working with OGM data more precise and sensitive detection methods for genomic research.
We believe the upgrades announced today will improve researchers’ ability to visualize, interpret and report results in a streamlined process that offers greater utility for the identification of critical cancer signatures from a genome-wide perspective,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.

Jushi Holdings Inc. Reports First Quarter 2024 Financial Results

Retrieved on:

星期四, 五月 9, 2024

Net income, Stock, SVS, Cannabis, Adjustment, Security (finance)

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, is pleased to announce its financial results for the first quarter ended March 31, 2024 (“Q1 2024”). All financial information is unaudited and provided in U.S. dollars unless otherwise indicated and is prepared under U.S. Generally Accepted Accounting Principles (“GAAP”).

Key Points:

Net Loss of $18.4 Million, Compared to $12.4 Million in Q1 2023
BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) ( OTCQX: JUSHF ), a vertically integrated, multi-state cannabis operator, is pleased to announce its financial results for the first quarter ended March 31, 2024 (“Q1 2024”).
All financial information is unaudited and provided in U.S. dollars unless otherwise indicated and is prepared under U.S. Generally Accepted Accounting Principles (“GAAP”).
“I am proud to share that our Q1 2024 gross profit margin is up to 49.4%, with Adjusted EBITDA further improving to 20.4% of revenue for the quarter.
Additionally, our positioning in high-growth markets has provided an encouraging start to 2024, and we believe there are several exciting regulatory developments on the horizon.”
Financial Results for the First Quarter Ended March 31, 2024

Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress

Retrieved on:

星期三, 五月 8, 2024

Reiterated full year 2024 revenue guidance of $37.0 to $41.0 million; revenue for the second quarter of 2024 is expected to be $7.8 to $8.2 million.

Key Points:

Reiterated full year 2024 revenue guidance of $37.0 to $41.0 million; revenue for the second quarter of 2024 is expected to be $7.8 to $8.2 million.
GAAP gross margin for the first quarter of 2024 was 32%, compared to 28% from the first quarter of 2023.
First quarter 2024 non-GAAP gross margin was 34%, compared to 30% from the first quarter of 2023.
Gülsen Kama, chief financial officer at Bionano added, “Q1 2024 was an important quarter for the Company.

CesiumAstro Selected by Rocket Lab to Provide Multi-Beam Ka-Band Communications Payloads for its Space Development Agency Tranche 2 Transport Layer Constellation

Retrieved on:

星期二, 五月 7, 2024

CesiumAstro, an industry leader in active phased array communications technology for space and airborne systems, announced today that the company was selected by Rocket Lab (Nasdaq: RKLB) to provide its Vireo active electronically scanned array (AESA) radio frequency (RF) communications payload for integration on 18 space vehicles (SVs) supporting the Space Development Agency’s (SDA’s) Tranche 2 Transport Layer (T2TL).

Key Points:

CesiumAstro, an industry leader in active phased array communications technology for space and airborne systems, announced today that the company was selected by Rocket Lab (Nasdaq: RKLB) to provide its Vireo active electronically scanned array (AESA) radio frequency (RF) communications payload for integration on 18 space vehicles (SVs) supporting the Space Development Agency’s (SDA’s) Tranche 2 Transport Layer (T2TL).
Image courtesy: CesiumAstro
CesiumAstro’s Vireo payload is the culmination of more than seven years of the company’s AESA research, development, testing, and manufacturing.
When fully operational, the Transport Layer constellation will include hundreds of SVs operating in low-Earth orbit, including 90 total Beta Program configurations.
“We’re pleased to be flying the CesiumAstro Vireo communications payload,” said Rocket Lab’s Vice President of Space Systems, Brad Clevenger.

NANO MAGIC UPDATE

Retrieved on:

星期三, 四月 24, 2024

Nanotechnology, Walmart, Eyewear, Glass, Magic, OTC, Annual report, Menards, Micro Center, SVS, Fastenal, Walgreens, Uline, Advance Auto Parts, Vision Source

Madison Heights, Michigan, April 24, 2024 (GLOBE NEWSWIRE) -- Nano Magic, Inc. (OTC: NMGX) (“Nano Magic” or the “Company”), a leader in innovative nanotechnology powered cleaning solutions, protective coatings, and anti-fog products provided an update from President & CEO Tom Berman following the Company’s filing on April 3, 2024, of its Annual Report on Form 10-K for the year ended December 31, 2023.

Key Points:

Madison Heights, Michigan, April 24, 2024 (GLOBE NEWSWIRE) -- Nano Magic, Inc. (OTC: NMGX) (“Nano Magic” or the “Company”), a leader in innovative nanotechnology powered cleaning solutions, protective coatings, and anti-fog products provided an update from President & CEO Tom Berman following the Company’s filing on April 3, 2024, of its Annual Report on Form 10-K for the year ended December 31, 2023.
Nano Magic continues to focus on building its brand by selling Nano Magic branded products direct-to-consumer, through national retailers, and in specialty channels such as the optical and safety industries.
Nano Magic also secured new programs with national retailers including Menards, Kroger/Fred Meyer, and Kinney Drugs; Nano Magic also extended existing programs with Walmart, Advanced Auto Parts, Best Buy, Micro Center, and Spartan Nash among others.
Nano Magic has also developed new partnerships with Global Optics, Cherry Optical, and Western Optical Supply in the optical channel.

Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing

Retrieved on:

星期三, 四月 24, 2024

Nanopore, Nanopore sequencing, OGM, University Medical Center, Doctor of Philosophy, Leukemia, BMA, Genomics, Bone marrow, SVS, SAN, University Medical Center Groningen

OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM.

Key Points:

OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM.
Some of OGM’s novel findings, however, are difficult for other methods to validate, because of their resolution limitations.
The study results highlight OGM’s ability to provide researchers with a more comprehensive understanding of leukemia subtypes and the potential of targeted Cas9-directed Nanopore sequencing to validate new findings efficiently and at high resolution, compared to other genome analysis methods, including short read or other long read sequencing methods.
“We were pleased to see researchers conclude that the findings detected by OGM in leukemia samples were robust and superior to classical cytogenetic methods.

Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence

Retrieved on:

星期三, 四月 17, 2024

Cytogenetics, Pregnancy, NMPA, OGM, Partnership, OEM, Doctor of Philosophy, Research, Artificial intelligence, Karyotype, Fertilisation, Genomics, Bone marrow, SVS, SAN, Medical device

Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology.

Key Points:

Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology.
Diagens has received Class I registration and approval for Bionano’s OGM reagents from China's NMPA and will register the Saphyr™ instrument with NMPA for clinical use in reproductive health.
“As a pioneer in AI chromosome karyotype analysis, we are very happy to establish a partnership with Bionano and to jointly explore the reproductive health market.
Diagens offers cutting-edge AI technology to help our customers to achieve a better overall success rate of in vitro fertilization.

Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing

Retrieved on:

星期四, 四月 11, 2024

B-ALL, OGM, RNA, WGS, Genetic variation, Doctor of Philosophy, Research, Leukemia, Bone marrow, Biomarker, Genomics, Whole genome sequencing, Cancer, SVS, SAN, Vaccine

The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM to obtain a comprehensive analysis of genetic variation.

Key Points:

The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM to obtain a comprehensive analysis of genetic variation.
The study concluded that OGM together with WGS can potentially identify new therapeutic targets and improve personalized medicine in pediatric leukemia and other cancers by providing a more complete view of genome variation, including structural variation.
The study findings showed that, of the 3,075 total SVs detected in the B-ALL samples, 1,255 were uniquely detected by OGM.
The study also found that WGS detected 66 gene fusions, and that OGM was able to detect an additional 56 fusions that were missed by WGS.

4Front Ventures Announces Issuance of Securities to Consultants, Directors, and Officers

Retrieved on:

星期三, 四月 24, 2024

Consultant, SVS, Death, Disability, Security (finance)

PHOENIX, April 24, 2024 /PRNewswire/ - 4Front Ventures Corp .

Key Points:

PHOENIX, April 24, 2024 /PRNewswire/ - 4Front Ventures Corp .
(CSE: FFNT) (OTCQX: FFNTF) ("4Front" or the "Company"), a vertically integrated, multi-state cannabis operator and retailer, announced that it has authorized the issuance of certain securities in consideration for services provided by consultants, directors, and officers.
Further, the Company has agreed to issue 5,483,600 purchase warrants convertible into SVS (each a "Warrant") to settle debt owed to a service provider.
Each Warrant will be exercisable at US$0.07 into one SVS for a period of 4 years upon the satisfaction of specified commercial milestones.

Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics

Retrieved on:

星期三, 四月 3, 2024

Sarcoma, Diagnosis, KT, Oncogene, SAN, Neoplasm, Research, Cancer, Doctor of Philosophy, CDKN2A, Workflow, Karyotype, FISH, Genomics, Chromothripsis, SVS, Prognosis, Aberration, OGM, Medical imaging

Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.

Key Points:

Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.
The detection of SVs and CNVs remains challenging and typically requires multiple traditional cytogenetic techniques.
In this study, researchers demonstrated OGM’s ability to detect aberrations as small as 500 bp, which is approximately 10,000-fold higher resolution than that of KT.
As shown in this study, OGM can provide better characterization of the genomic complexity of sarcoma samples when compared to traditional cytogenetic techniques, due to the workflow’s high resolution and comprehensive, genome-wide analysis.